The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

By H. Maeda. Advances in Enzyme Regulation, 2001

2,337 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Oncology

View Paper: https://www.semanticscholar.org/paper/8b331a41ea05660874bdcf24637cca8e209031be

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Xiaohua Huang
2. M. El-Sayed
3. I. El-Sayed
4. N. Bertrand
5. N. Kamaly
6. Miqin Zhang
7. Xiaoyang Xu
8. Jun Wu

In Biomedical Engineering

1. Xiaohua Huang
2. M. El-Sayed
3. I. El-Sayed
4. Naomi J. Halas
5. N. Bertrand
6. Miqin Zhang
7. E. Dreaden
8. Xiaoyang Xu

In Oncology

1. I. El-Sayed
2. J. O’Sullivan
3. K. El-Say
4. Hossam S. El-Sawy
5. Peter L. Choyke
6. O. Farokhzad
7. Shuming Nie
8. M. El-Sayed

Citations in the corpus

• Nanoparticles for drug delivery in cancer treatment. (2008, background): “This feature is termed the enhanced ermeability and retention (EPR) effect and favors tumor nterstitial drug accumulation [8,9].”
• Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer (2009, background): “In particular for liposomal daunorubicin (DaunoXome), liposomal doxorubicin (D-99, MyocetTM), and pegylated liposomal doxorubicin (Doxil and Caelyx), the delivery system enables the enhanced permeation and retention (EPR) effect.(52,53) In fact the small dimension ( 300 nm) enables the drug to accum”
• Targeted delivery of low molecular drugs using chitosan and its derivatives. (2010, background): “discovered the selective accumulation of macromolecular drugs in tumor tissues [63,64].”
• Gold nanoparticles as novel agents for cancer therapy. (2012, background): “have leaky, immature vasculature with wider fenestrations than normal mature blood vessels [15].”
• Polymeric nanoparticles: Promising platform for drug delivery. (2017, background): “…toxicity to normal cells, as the PNPs designed for targeted drug delivery systems (TDDS) can increase the tissue specific anticancer active ingredients delivery through either an active or passive targeting tumours deprived of affecting non-cancerous regions (Maeda, 2001; Yu et al., 2012).”